DCSIMG
Chronic Insomnia & Next-Day Function
Sanofi Logo
Text Size – + |   FAQs  |  Site Map  |  Contact Us  |   Consumer Site
For U.S. Healthcare Professionals Only
AMBIEN CR (Zolpidem Tartrate Extended Release) Sleep Aid

FOR HEALTHCARE PROFESSIONALS

Give your patients
a good night's sleep...
FOR LESS

Share the AMBIEN CR Offer Card with your patients for up to $20* off each of their next 12 prescriptions.

Learn More
Skip Navigation Links

Chronic Insomnia & Sleep-Related Next-Day Function

Email to Your Friend Send to a Friend   Print Print Page
Chronic insomnia and sleep-related next-day function

Chronic insomnia is associated with substantial functional impairment, including work-related performance.3 And according to the National Sleep Foundation's 2008 Sleep in America Poll, 25% of respondents said that insufficient sleep and sleepiness interfered with their daily activities.12

Multiple clinical trials show significant improvement 2,3,6

In multiple clinical trials, patients taking AMBIEN CR showed statistically significant improvement in sleep-related next-day function vs. placebo.2

Improvement in 2:

  • Sleep quality
  • Morning energy
  • Morning concentration
  • Impact of sleep on daily activities
Better concentration and less morning sleepiness

In a 24-week study, patients reported improved ability to concentrate and significantly less morning sleepiness vs. placebo.2

IMPROVEMENTS IN MORNING SLEEPINESS THROUGH WEEK 24

n=1,016.

*|P<0.0001.

†Results of a multicenter, double-blind, placebo-controlled, 24-week evaluation of AMBIEN CR 12.5 mg, 3 to 7 tablets a week in adults with chronic primary insomnia.

‡Based on a scale of 0 to 10, where 0 was very sleepy and 10 was not at all sleepy.

Increased work efficiency 3

Significant improvements were seen in work performance at 12 weeks, sustained over 24 weeks3

  • Work productivity—Patients assessed their ability to meet demands for quantity and quality of work while completing tasks in a timely manner
  • Time management—Patients assessed their ability to meet time demands and cope with scheduling pressures
  • Less time spent struggling with job performance—Lower scores indicate better time management and work output from baseline
  • The primary objective of the analysis was to assess improvement at 12 weeks. Similar results were observed from baseline to 24 weeks, end of treatment
PATIENTS TAKING AMBIEN CR SPENT LESS TIME STUGGLING WITH JOB PERFORMANCE

§Scores were evaluated until end of treatment / premature discontinuation in order to confirm the results at Week 12.

||P<0.0001 at Weeks 4, 12, and 24.

¶The Work Limitations Questionnaire (WLQ) is a self-administered questionnaire measuring the degree to which health problems interfere with ability to perform job roles. Respondents were asked to rate their level of performance on 10 specific job demands.

**n values represent end-of-treatment populations.

††Graph derived from WLQ Time Management scale.


Next: AMBIEN CR Mechanism of Action

pagedivide

* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions), depending on your out-of-pocket costs. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, or any private payor in the state of Massachusetts and where prohibited by law.

AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

IMPORTANT SAFETY INFORMATION

In elderly or debilitated patients, or patients with hepatic insufficiency, the recommended dose is 6.25 mg and patients should be closely monitored. Due to its rapid onset of action, patients should take AMBIEN CR right before going to bed and when ready for sleep. Patients should not take AMBIEN CR unless they are prepared to get a full night’s sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN CR or any other sleep medication. Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN CR and in rare cases may be fatal. Patients who develop angioedema should not be rechallenged. In primarily depressed patients, worsening of depression, including risk of suicidal thoughts or actions, including completed suicides, have been reported. The most commonly observed adverse effects in controlled clinical trials were headache, somnolence, and dizziness. Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN CR or any other hypnotic. AMBIEN CR is a Schedule IV controlled substance.

Please refer to the full prescribing information.